Skip Navigation

This Article
Right arrow Abstract
Right arrow FREE Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow Request Permissions

Estrogen Receptor–Positive, Progesterone Receptor–Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance
J. Natl. Cancer Inst. Arpino et al. 97: 1254

Supplementary Tables

The following supplementary tables accompany this Article:

Files in this Data Supplement:

  • Supplementary Table 1 - Performance of HER-1 and -2 by ER+/PR+ and ER+/PR- phenotype
  • Supplementary Table 2 - Clinical and biological characteristics between patients with versus without HER-1 and/or HER-2 evaluations (ER+/PR+ and ER+/PR- tumors only)
  • Supplementary Table 3 - Clinical and biological characteristics in ER+/PR+ versus ER+/PR- tumors in tamoxifen-treated patients with HER-1 and/or HER-2 evaluations



This Article
Right arrow Abstract
Right arrow FREE Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow Request Permissions